CN109331027A - 用于减轻炎性疼痛或相关病症的包含唑来膦酸或相关化合物的组合物 - Google Patents
用于减轻炎性疼痛或相关病症的包含唑来膦酸或相关化合物的组合物 Download PDFInfo
- Publication number
- CN109331027A CN109331027A CN201811173434.6A CN201811173434A CN109331027A CN 109331027 A CN109331027 A CN 109331027A CN 201811173434 A CN201811173434 A CN 201811173434A CN 109331027 A CN109331027 A CN 109331027A
- Authority
- CN
- China
- Prior art keywords
- zoledronic acid
- technical solution
- pain
- dosage form
- mankind
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 title claims abstract description 183
- 229960004276 zoledronic acid Drugs 0.000 title claims abstract description 177
- 206010065390 Inflammatory pain Diseases 0.000 title claims abstract description 32
- 150000001875 compounds Chemical class 0.000 title abstract description 17
- 239000000203 mixture Substances 0.000 title abstract description 9
- 208000002193 Pain Diseases 0.000 claims abstract description 110
- 230000036407 pain Effects 0.000 claims abstract description 108
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 239000002552 dosage form Substances 0.000 claims description 116
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 40
- 206010003246 arthritis Diseases 0.000 claims description 28
- 239000002253 acid Substances 0.000 claims description 26
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 14
- 150000003851 azoles Chemical class 0.000 claims description 14
- 230000003442 weekly effect Effects 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical group [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 7
- 208000008035 Back Pain Diseases 0.000 claims description 4
- 208000008930 Low Back Pain Diseases 0.000 claims description 3
- -1 bisphosphonate compounds Chemical class 0.000 abstract description 11
- 239000006186 oral dosage form Substances 0.000 abstract description 10
- 229940122361 Bisphosphonate Drugs 0.000 abstract description 8
- 150000004663 bisphosphonates Chemical class 0.000 abstract 2
- 239000000243 solution Substances 0.000 description 194
- 238000000034 method Methods 0.000 description 120
- 241000124008 Mammalia Species 0.000 description 39
- 208000011580 syndromic disease Diseases 0.000 description 30
- 239000007787 solid Substances 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 229940127554 medical product Drugs 0.000 description 21
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 201000010099 disease Diseases 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000000116 mitigating effect Effects 0.000 description 11
- 238000005259 measurement Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 150000003009 phosphonic acids Chemical class 0.000 description 9
- 238000011552 rat model Methods 0.000 description 9
- 208000001132 Osteoporosis Diseases 0.000 description 8
- 210000000214 mouth Anatomy 0.000 description 8
- 208000010392 Bone Fractures Diseases 0.000 description 7
- 206010017076 Fracture Diseases 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 6
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 6
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 229960002286 clodronic acid Drugs 0.000 description 6
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 6
- 230000006835 compression Effects 0.000 description 6
- 238000007906 compression Methods 0.000 description 6
- 229950006971 incadronic acid Drugs 0.000 description 6
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical class NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 6
- 201000008482 osteoarthritis Diseases 0.000 description 6
- 230000037040 pain threshold Effects 0.000 description 6
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 6
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 5
- 208000010191 Osteitis Deformans Diseases 0.000 description 5
- 208000000114 Pain Threshold Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 5
- 229960004343 alendronic acid Drugs 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 229960004585 etidronic acid Drugs 0.000 description 5
- 210000001872 metatarsal bone Anatomy 0.000 description 5
- 229950010733 neridronic acid Drugs 0.000 description 5
- 229950004969 olpadronic acid Drugs 0.000 description 5
- 229960003978 pamidronic acid Drugs 0.000 description 5
- 229960000759 risedronic acid Drugs 0.000 description 5
- 159000000000 sodium salts Chemical group 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 229960005324 tiludronic acid Drugs 0.000 description 5
- 208000004454 Hyperalgesia Diseases 0.000 description 4
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 4
- 208000027067 Paget disease of bone Diseases 0.000 description 4
- 208000016738 bone Paget disease Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229960005236 ibandronic acid Drugs 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 208000007815 Acquired Hyperostosis Syndrome Diseases 0.000 description 3
- 208000018084 Bone neoplasm Diseases 0.000 description 3
- 206010058019 Cancer Pain Diseases 0.000 description 3
- 208000025962 Crush injury Diseases 0.000 description 3
- 208000012659 Joint disease Diseases 0.000 description 3
- 201000004854 SAPHO syndrome Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- OPQQEYHAVUNQNA-UHFFFAOYSA-L disodium;hydroxy-[1-hydroxy-1-[hydroxy(oxido)phosphoryl]-2-imidazol-1-ylethyl]phosphinate Chemical group [Na+].[Na+].OP(=O)([O-])C(P(O)([O-])=O)(O)CN1C=CN=C1 OPQQEYHAVUNQNA-UHFFFAOYSA-L 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000003447 ipsilateral effect Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 208000036487 Arthropathies Diseases 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000014677 Periarticular disease Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 201000011143 bone giant cell tumor Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007958 cherry flavor Substances 0.000 description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 description 2
- 210000000078 claw Anatomy 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 201000010103 fibrous dysplasia Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229910021485 fumed silica Inorganic materials 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 239000012744 reinforcing agent Substances 0.000 description 2
- 108010048734 sclerotin Proteins 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000942118 Homo sapiens C-reactive protein Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000001981 hip bone Anatomy 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000008771 sex reversal Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 206010043827 tibia fracture Diseases 0.000 description 1
- 229940019375 tiludronate Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical class [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (23)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261646538P | 2012-05-14 | 2012-05-14 | |
| US61/646,538 | 2012-05-14 | ||
| US201261647478P | 2012-05-15 | 2012-05-15 | |
| US61/647,478 | 2012-05-15 | ||
| US201261654292P | 2012-06-01 | 2012-06-01 | |
| US201261654383P | 2012-06-01 | 2012-06-01 | |
| US61/654,292 | 2012-06-01 | ||
| US61/654,383 | 2012-06-01 | ||
| US201261655541P | 2012-06-05 | 2012-06-05 | |
| US201261655527P | 2012-06-05 | 2012-06-05 | |
| US61/655,541 | 2012-06-05 | ||
| US61/655,527 | 2012-06-05 | ||
| US201361762225P | 2013-02-07 | 2013-02-07 | |
| US61/762,225 | 2013-02-07 | ||
| US201361764563P | 2013-02-14 | 2013-02-14 | |
| US61/764,563 | 2013-02-14 | ||
| US201361767676P | 2013-02-21 | 2013-02-21 | |
| US201361767647P | 2013-02-21 | 2013-02-21 | |
| US61/767,647 | 2013-02-21 | ||
| US61/767,676 | 2013-02-21 | ||
| US201361803721P | 2013-03-20 | 2013-03-20 | |
| US61/803,721 | 2013-03-20 | ||
| CN201380025570.XA CN104349781A (zh) | 2012-05-14 | 2013-05-14 | 用于减轻炎性疼痛或相关病症的包含唑来膦酸或相关化合物的组合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380025570.XA Division CN104349781A (zh) | 2012-05-14 | 2013-05-14 | 用于减轻炎性疼痛或相关病症的包含唑来膦酸或相关化合物的组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109331027A true CN109331027A (zh) | 2019-02-15 |
Family
ID=49549077
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380025570.XA Pending CN104349781A (zh) | 2012-05-14 | 2013-05-14 | 用于减轻炎性疼痛或相关病症的包含唑来膦酸或相关化合物的组合物 |
| CN201811173434.6A Pending CN109331027A (zh) | 2012-05-14 | 2013-05-14 | 用于减轻炎性疼痛或相关病症的包含唑来膦酸或相关化合物的组合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380025570.XA Pending CN104349781A (zh) | 2012-05-14 | 2013-05-14 | 用于减轻炎性疼痛或相关病症的包含唑来膦酸或相关化合物的组合物 |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US20130303488A1 (enExample) |
| EP (2) | EP3323418A1 (enExample) |
| JP (2) | JP2015518828A (enExample) |
| KR (3) | KR20160139050A (enExample) |
| CN (2) | CN104349781A (enExample) |
| AU (3) | AU2013262995B2 (enExample) |
| CA (2) | CA2987470A1 (enExample) |
| CY (1) | CY1120503T1 (enExample) |
| DK (1) | DK2849758T3 (enExample) |
| ES (1) | ES2667535T3 (enExample) |
| HK (1) | HK1255373A1 (enExample) |
| HR (1) | HRP20180606T1 (enExample) |
| HU (1) | HUE038905T2 (enExample) |
| LT (1) | LT2849758T (enExample) |
| NZ (1) | NZ702414A (enExample) |
| PL (1) | PL2849758T3 (enExample) |
| PT (1) | PT2849758T (enExample) |
| RS (1) | RS57294B1 (enExample) |
| SI (1) | SI2849758T1 (enExample) |
| SM (1) | SMT201800212T1 (enExample) |
| WO (1) | WO2013173330A1 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| PT2459176T (pt) | 2009-07-31 | 2017-12-11 | Gruenenthal Gmbh | Método de cristalização e biodisponibilidade |
| WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| US9694023B2 (en) | 2012-05-14 | 2017-07-04 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
| US10111837B2 (en) | 2012-05-14 | 2018-10-30 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds |
| US10034890B2 (en) | 2012-05-14 | 2018-07-31 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10413561B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
| US9877977B2 (en) | 2012-05-14 | 2018-01-30 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9289441B2 (en) | 2014-08-08 | 2016-03-22 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
| US9669040B2 (en) | 2012-05-14 | 2017-06-06 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9827256B2 (en) | 2014-05-27 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating lower back pain |
| US9662343B2 (en) | 2012-05-14 | 2017-05-30 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10004756B2 (en) | 2014-05-15 | 2018-06-26 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9655908B2 (en) | 2012-05-14 | 2017-05-23 | Antecip Bioventures Ii Llc | Neridronic acid molecular complex for treating complex regional pain syndrome |
| US10039773B2 (en) | 2012-05-14 | 2018-08-07 | Antecip Bioventures Ii Llc | Neridronic acid for treating arthritis |
| US10028969B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9707247B2 (en) | 2012-05-14 | 2017-07-18 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| US9675626B2 (en) | 2012-05-14 | 2017-06-13 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9895383B2 (en) * | 2012-05-14 | 2018-02-20 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10413560B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
| US10463682B2 (en) | 2012-05-14 | 2019-11-05 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain |
| US10493085B2 (en) | 2012-05-14 | 2019-12-03 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
| US9956238B2 (en) | 2014-05-15 | 2018-05-01 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| US9956237B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
| US9867840B2 (en) | 2014-05-27 | 2018-01-16 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US20140349974A1 (en) * | 2014-08-12 | 2014-11-27 | Antecip Bioventures Ii Llc | Zoledronic acid dosage forms for the treatment of pain |
| US9427403B2 (en) | 2012-05-14 | 2016-08-30 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
| US10080765B2 (en) | 2012-05-14 | 2018-09-25 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US9925203B2 (en) | 2012-05-14 | 2018-03-27 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| US9861648B2 (en) | 2012-05-14 | 2018-01-09 | Antecip Boiventures Ii Llc | Osteoclast inhibitors for knee conditions |
| US9770457B2 (en) | 2012-05-14 | 2017-09-26 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesion |
| US9820999B2 (en) | 2012-05-14 | 2017-11-21 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US9827192B2 (en) | 2012-05-14 | 2017-11-28 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9700570B2 (en) | 2014-05-27 | 2017-07-11 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10092581B2 (en) | 2014-05-15 | 2018-10-09 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
| US9844559B2 (en) | 2012-05-14 | 2017-12-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating bone marrow lesions |
| US9717747B2 (en) | 2012-05-14 | 2017-08-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
| US9789128B2 (en) | 2012-05-14 | 2017-10-17 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9999629B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9707245B2 (en) | 2012-05-14 | 2017-07-18 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US9943531B2 (en) | 2014-08-08 | 2018-04-17 | Antecip Bioventures Ii Llc | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
| US9795622B2 (en) | 2012-05-14 | 2017-10-24 | Antecip Bioventures Ii Llc | Neridronic acid for treating pain associated with a joint |
| US9956234B2 (en) | 2012-05-14 | 2018-05-01 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
| US9211257B2 (en) | 2012-05-14 | 2015-12-15 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for knee conditions |
| WO2015184003A1 (en) * | 2014-05-27 | 2015-12-03 | Antecip Bioventures Ii Llp | Osteoclast inhibitors for pain |
| US10028908B2 (en) | 2012-05-14 | 2018-07-24 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10173986B2 (en) | 2012-05-14 | 2019-01-08 | Antecip Bioventures Ii Llc | Methods for the safe administration of imidazole or imidazolium compounds |
| US8802658B2 (en) | 2012-05-14 | 2014-08-12 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| WO2015060924A1 (en) * | 2013-10-25 | 2015-04-30 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| US9782421B1 (en) | 2012-05-14 | 2017-10-10 | Antecip Bioventures Ii Llc | Neridronic acid molecular complex for treating complex regional pain syndrome |
| US8865757B1 (en) | 2014-05-28 | 2014-10-21 | Antecip Bioventures Ii Llp | Therapeutic compositions comprising imidazole and imidazolium compounds |
| US10350227B2 (en) | 2012-05-14 | 2019-07-16 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US9999628B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| US9867839B2 (en) | 2012-05-14 | 2018-01-16 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for joint conditions |
| US10016446B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone |
| US11654152B2 (en) | 2012-05-14 | 2023-05-23 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| US10016445B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9901589B2 (en) | 2012-05-14 | 2018-02-27 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US9616078B2 (en) | 2012-05-14 | 2017-04-11 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
| US9949993B2 (en) | 2012-05-14 | 2018-04-24 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| CN104969556A (zh) | 2013-01-08 | 2015-10-07 | Lg电子株式会社 | 处理视频信号的方法和设备 |
| US20170182072A1 (en) * | 2014-05-27 | 2017-06-29 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| CN106456610A (zh) * | 2014-05-27 | 2017-02-22 | 安泰赛普生物风投二代有限责任公司 | 用于疼痛的破骨细胞抑制剂 |
| SG10201706414SA (en) * | 2014-05-27 | 2017-09-28 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for pain |
| US9079927B1 (en) | 2014-05-27 | 2015-07-14 | Antecip Bioventures Ii Llc | Substituted imidazolium compounds for treating disease |
| CA3194798A1 (en) * | 2014-05-27 | 2015-12-03 | Antecip Bioventures Ii Llc | Osteoclast inhibitors for pain |
| US9127069B1 (en) | 2014-06-11 | 2015-09-08 | Antecip Bioventures LLC | Compositions comprising rank/rankl antagonists and related compounds for treating pain |
| US9688765B2 (en) | 2014-06-11 | 2017-06-27 | Antecip Bioventures Ii Llc | Methods using RANK/RANKL antagonist antibodies for treating pain |
| PT3206694T (pt) * | 2014-10-15 | 2020-09-22 | Abiogen Pharma Spa | Utilização de ácido neridrónico ou do seu sal para o tratamento da osteoartrose |
| EP3362071A4 (en) * | 2015-09-18 | 2019-07-17 | Grünenthal GmbH | CRYSTALLIZATION PROCESS AND BIOVERABILITY |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
| US20190328755A1 (en) * | 2018-04-30 | 2019-10-31 | Grunenthal Gmbh | Methods of treating complex regional pain syndrome (crps) or symptoms comprising administration of neridronic acid |
| CN109908159B (zh) * | 2019-03-15 | 2021-12-07 | 暨南大学 | 唑来膦酸和有机硒化合物联用在制备抗肿瘤药物中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002043738A2 (en) * | 2000-11-29 | 2002-06-06 | Novartis Ag | Use of bisphosphonates for pain treatment |
| CN1964715A (zh) * | 2004-05-06 | 2007-05-16 | 默克公司 | 治疗狗的关节炎状况的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4639338A (en) * | 1984-08-06 | 1987-01-27 | Ciba-Geigy Corporation | Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate |
| WO2000038693A1 (en) * | 1998-12-25 | 2000-07-06 | Toray Industries, Inc. | Interleukin-6 production inhibitors |
| JP2005525368A (ja) * | 2002-03-04 | 2005-08-25 | メディミューン，インコーポレーテッド | インテグリンαｖβ３アンタゴニストをＨＭＧ−ＣｏＡ還元酵素阻害剤またはビスフォスフォネートと併用投与する障害の予防または治療方法 |
| US7875597B2 (en) * | 2002-07-24 | 2011-01-25 | New York University | Treatment of spinal mechanical pain |
| CA2501381A1 (en) * | 2002-10-15 | 2004-04-29 | Novartis Ag | Method of administering bisphosphonates |
| US20050054616A1 (en) * | 2003-07-03 | 2005-03-10 | Judith Aronhime | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation |
| AR046773A1 (es) * | 2003-12-23 | 2005-12-21 | Novartis Ag | Formulaciones farmaceuticas de bisfosfonatos |
| WO2005072747A1 (ja) * | 2004-02-02 | 2005-08-11 | Ono Pharmaceutical Co., Ltd. | 骨吸収抑制剤 |
| EP1745007A2 (en) * | 2004-04-16 | 2007-01-24 | Emisphere Technologies, Inc. | 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents |
| PT1753395E (pt) * | 2004-05-24 | 2010-10-21 | Warner Chilcott Co Llc | Forma entérica sólida de dosagem oral de um bisfosfonato contendo um agente quelante |
| JP2008533173A (ja) * | 2005-03-17 | 2008-08-21 | エラン ファーマ インターナショナル リミテッド | ナノ粒子ビスホスホネート組成物 |
| US7704977B2 (en) * | 2006-04-07 | 2010-04-27 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| WO2010099255A1 (en) * | 2009-02-25 | 2010-09-02 | Merrion Research Iii Limited | Composition and drug delivery of bisphosphonates |
| EP3158867B1 (en) * | 2009-07-31 | 2018-12-12 | Grünenthal GmbH | A method for increasing the aqueous solubility of a bisphosphonic acid or a bisphosphonate |
| JP5792748B2 (ja) * | 2010-02-06 | 2015-10-14 | タール ファーマシューティカルズ，インコーポレイテッド | 結晶化法及びバイオアベイラビリティ |
-
2013
- 2013-05-14 JP JP2015512753A patent/JP2015518828A/ja active Pending
- 2013-05-14 EP EP17206293.7A patent/EP3323418A1/en not_active Withdrawn
- 2013-05-14 US US13/894,274 patent/US20130303488A1/en not_active Abandoned
- 2013-05-14 EP EP13791356.2A patent/EP2849758B1/en active Active
- 2013-05-14 US US13/894,262 patent/US20130303487A1/en not_active Abandoned
- 2013-05-14 PT PT137913562T patent/PT2849758T/pt unknown
- 2013-05-14 CN CN201380025570.XA patent/CN104349781A/zh active Pending
- 2013-05-14 SM SM20180212T patent/SMT201800212T1/it unknown
- 2013-05-14 WO PCT/US2013/040939 patent/WO2013173330A1/en not_active Ceased
- 2013-05-14 RS RS20180483A patent/RS57294B1/sr unknown
- 2013-05-14 US US13/894,252 patent/US20130303486A1/en not_active Abandoned
- 2013-05-14 KR KR1020167032879A patent/KR20160139050A/ko not_active Ceased
- 2013-05-14 HU HUE13791356A patent/HUE038905T2/hu unknown
- 2013-05-14 DK DK13791356.2T patent/DK2849758T3/en active
- 2013-05-14 ES ES13791356.2T patent/ES2667535T3/es active Active
- 2013-05-14 LT LTEP13791356.2T patent/LT2849758T/lt unknown
- 2013-05-14 KR KR1020197000076A patent/KR20190004381A/ko not_active Ceased
- 2013-05-14 KR KR1020147034760A patent/KR20150035597A/ko not_active Ceased
- 2013-05-14 NZ NZ702414A patent/NZ702414A/en unknown
- 2013-05-14 AU AU2013262995A patent/AU2013262995B2/en active Active
- 2013-05-14 CA CA2987470A patent/CA2987470A1/en not_active Abandoned
- 2013-05-14 PL PL13791356T patent/PL2849758T3/pl unknown
- 2013-05-14 HR HRP20180606TT patent/HRP20180606T1/hr unknown
- 2013-05-14 CA CA2873742A patent/CA2873742C/en active Active
- 2013-05-14 SI SI201330993T patent/SI2849758T1/en unknown
- 2013-05-14 CN CN201811173434.6A patent/CN109331027A/zh active Pending
- 2013-05-14 US US13/894,244 patent/US20130303485A1/en not_active Abandoned
-
2016
- 2016-02-03 US US15/014,994 patent/US20160151398A1/en not_active Abandoned
- 2016-11-08 AU AU2016256701A patent/AU2016256701B2/en active Active
-
2018
- 2018-04-11 JP JP2018075822A patent/JP2018127477A/ja active Pending
- 2018-05-03 CY CY20181100458T patent/CY1120503T1/el unknown
- 2018-08-10 AU AU2018214132A patent/AU2018214132B2/en active Active
- 2018-11-14 HK HK18114512.0A patent/HK1255373A1/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002043738A2 (en) * | 2000-11-29 | 2002-06-06 | Novartis Ag | Use of bisphosphonates for pain treatment |
| CN1964715A (zh) * | 2004-05-06 | 2007-05-16 | 默克公司 | 治疗狗的关节炎状况的方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109331027A (zh) | 用于减轻炎性疼痛或相关病症的包含唑来膦酸或相关化合物的组合物 | |
| JP7136487B2 (ja) | 増強した経口バイオアベイラビリティーを有する経口医薬組成物 | |
| US8822436B1 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating disease | |
| AU2014340649A1 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating disease | |
| HK40002583A (en) | Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions | |
| WO2016172453A1 (en) | Pharmacodynamic effects after oral administration of zoledronic acid or related compounds | |
| HK1228800B (en) | Compositions for oral administration of zoledronic acid or related compounds for treating disease | |
| HK1228800A1 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40002583 Country of ref document: HK |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190215 |